JAVIER
ESCANED BARBOSA
Profesor asociado de Ciencias de la Salud
![Foto de JAVIER](/img/uploaded/B1C208A8E1820F13282153D4BA39B96E.jpg)
![Foto de Policlinico Umberto I](/img/noimage_org.png)
Policlinico Umberto I
Roma, ItaliaPublicaciones en colaboración con investigadores/as de Policlinico Umberto I (10)
2024
2023
-
Clinically Driven Revascularization in High-Risk Patients Treated With Ticagrelor Monotherapy After PCI: Insights from the Randomized TWILIGHT Trial
American Journal of Cardiology, Vol. 208, pp. 16-24
-
Dyspnea-Related Ticagrelor Discontinuation After Percutaneous Coronary Intervention
JACC: Cardiovascular Interventions, Vol. 16, Núm. 20, pp. 2514-2524
-
Ticagrelor with or without aspirin in high-risk patients with anaemia undergoing percutaneous coronary intervention: a subgroup analysis of the TWILIGHT trial
European Heart Journal - Cardiovascular Pharmacotherapy, Vol. 9, Núm. 4, pp. 328-336
2022
-
Bleeding and Ischemic Outcomes With Ticagrelor Monotherapy According to Body Mass Index
JACC: Cardiovascular Interventions, Vol. 15, Núm. 19, pp. 1948-1960
-
Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI: A Prespecified TWILIGHT Substudy
JACC: Cardiovascular Interventions, Vol. 15, Núm. 3, pp. 282-293
2021
-
Impact of Age on the Safety and Efficacy of Ticagrelor Monotherapy in Patients Undergoing PCI
JACC: Cardiovascular Interventions, Vol. 14, Núm. 13, pp. 1434-1446
-
Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR
European Heart Journal, Vol. 42, Núm. 45, pp. 4624-4634
-
Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD
European Heart Journal, Vol. 42, Núm. 45, pp. 4683-4693
2019
-
Ticagrelor with or without aspirin in high-risk patients after PCI
New England Journal of Medicine, Vol. 381, Núm. 21, pp. 2032-2042